Bronchitis
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- An acute or chronic inflammatory process affecting the bronchi.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Bronchitis
- Therapeutic area
- Pulmonology
- bronchitis
- bronchial infection
- bronchus inflammation
- inflammation of bronchus
- acute bronchitis
- chronic bronchitis
- Disease mechanisms
- Inflammatory
- All therapeutic areas
- Pulmonology
- Severity
- Mild
- MONDO ID
- MONDO:0003781
- Parent condition
- MONDO:0001358
Related records
Broader conditions (9)
- Bronchial disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Inflammatory disease
- Lower respiratory tract disorder
- Respiratory system disorder
- Tracheobronchitis
Narrower conditions (2)
- Chronic bronchitis
- Croup
Trials (141)
- A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
- A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
- A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients
- A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
- A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis
- A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients
- A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
- A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
- A Non-Interventional Safety Study of Balsamic Bactrim
- A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
- A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection(a Chinese Medicine Injection)Used in Hospitals in China
- A Registry Study on Reduning(a Chinese Medicine Injection)Used in Hospitals in China
- A Registry Study on Tanreqing(a Chinese Medicine Injection)Used in Hospitals in China
- A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals
- A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
- A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
- A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.
- A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria
- A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria
Approved drugs (3)
- Cefixime
- Menthol
- Terbutaline sulfate
Drugs in development (13)
- Alteplase Phase 2
- Amoxicillin Phase 3
- Arformoterol Phase 3
- Arformoterol tartrate Phase 3
- Azithromycin Phase 3
- Cilomilast Phase 3
- Clavulanic acid Phase 3
- Colistin Phase 3
- Formoterol Phase 3
- Levofloxacin Phase 3
- Omalizumab Phase 2
- Reslizumab Phase 2
- Sirolimus Phase 2
Other linked drugs (24)
- Aclidinium bromide
- Ambroxol
- Budesonide
- Clarithromycin
- Clofoctol
- Demeclocycline
- Erdosteine
- Etanercept
- Fluticasone furoate
- Fudosteine
- Garenoxacin mesylate
- Glycopyrronium bromide
- Indacaterol maleate
- Ipratropium
- Lascufloxacin
- Olodaterol hydrochloride
- Ozone
- Piperacillin sodium
- Plazomicin
- Sitafloxacin